A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vantictumab (Primary) ; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Adverse reactions
Sponsors OncoMed Pharmaceuticals

13 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.
08 May 2017 Status changed from recruiting to suspended, according to an OncoMed Pharmaceuticals media release.
08 May 2017 According to an OncoMed Pharmaceuticals media release, the company has put this program on hold. OncoMed has subsequently decided to cease dosing patients in the current vantictumab Phase 1b studies following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com